Last reviewed · How we verify
Neoadjuvant therapy
Neoadjuvant therapy refers to treatment administered before the primary surgical or definitive intervention to reduce tumor burden and improve outcomes.
Neoadjuvant therapy refers to treatment administered before the primary surgical or definitive intervention to reduce tumor burden and improve outcomes. Used for Locally advanced solid tumors (various cancer types) to improve surgical resectability and outcomes, Breast cancer, gastric cancer, esophageal cancer, and other malignancies where preoperative treatment is indicated.
At a glance
| Generic name | Neoadjuvant therapy |
|---|---|
| Also known as | None noted, Neoadjuvant chemotherapy combined with Serplulimab |
| Sponsor | Sun Yat-sen University |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Neoadjuvant therapy is a treatment strategy rather than a specific drug, typically involving chemotherapy, targeted therapy, immunotherapy, or radiation given before surgery or other definitive treatment. The goal is to shrink tumors, eliminate micrometastases, and improve resectability or response to subsequent treatment. This approach can improve overall survival and allow for less invasive surgical procedures.
Approved indications
- Locally advanced solid tumors (various cancer types) to improve surgical resectability and outcomes
- Breast cancer, gastric cancer, esophageal cancer, and other malignancies where preoperative treatment is indicated
Common side effects
- Chemotherapy-related toxicity (nausea, myelosuppression, neuropathy)
- Immunotherapy-related adverse events (if immunotherapy component used)
- Delayed wound healing or surgical complications
Key clinical trials
- Exemption of SLNB After Neoadjuvant Therapy for Triple-negative and Her2-positive Breast Cancer (NA)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma (PHASE2)
- Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neoadjuvant therapy CI brief — competitive landscape report
- Neoadjuvant therapy updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI